The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases by Hornemann, T et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2009
The SPTLC3 subunit of serine palmitoyltransferase generates short chain
sphingoid bases
Hornemann, T; Penno, A; Rütti, M F; Ernst, D; Kivrak-Pfiffner, F; Rohrer, L; von Eckardstein, A
Abstract: The enzyme serine palmitoyltransferase (SPT) catalyzes the rate-limiting step in the de novo
synthesis of sphingolipids. Previously the mammalian SPT was described as a heterodimer composed
of two subunits, SPTLC1 and SPTLC2. Recently we identified a novel third SPT subunit (SPTLC3).
SPTLC3 shows about 68% identity to SPTLC2 and also includes a pyridoxal phosphate consensus motif.
Here we report that the overexpression of SPTLC3 in HEK293 cells leads to the formation of two new
sphingoid base metabolites, namely C(16)-sphinganine and C(16)-sphingosine. SPTLC3-expressing cells
have higher in vitro SPT activities with lauryl- and myristoyl-CoA than SPTLC2-expressing cells, and
SPTLC3 mRNA expression levels correlate closely with the C(16)-sphinganine synthesis rates in various
human and murine cell lines. Approximately 15% of the total sphingolipids in human plasma contain a
C(16) backbone and are found in the high density and low density but not the very low density lipoprotein
fraction. In conclusion, we show that the SPTLC3 subunit generates C(16)-sphingoid bases and that
sphingolipids with a C(16) backbone constitute a significant proportion of human plasma sphingolipids.
DOI: 10.1074/jbc.M109.023192
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-24506
Accepted Version
Originally published at:
Hornemann, T; Penno, A; Rütti, M F; Ernst, D; Kivrak-Pfiffner, F; Rohrer, L; von Eckardstein, A (2009).
The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases. Journal of
Biological Chemistry, 284(39):26322-26330. DOI: 10.1074/jbc.M109.023192
THE SPTLC3 SUBUNIT OF SERINE-
PALMITOYLTRANSFERASE GENERATES SHORT CHAIN 
SPHINGOID BASES 
Thorsten Hornemann1*, Anke Penno1, Markus F. Rütti, Daniela Ernst, Fatma Kivrak-Pfiffner, 
Lucia Rohrer, Arnold von Eckardstein1 
Institute for Clinical Chemistry, University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, 
Switzerland 
1 Competence Center for Systems Physiology and Metabolic Diseases, Zurich 
* Corresponding Author: Institute for Clinical Chemistry, University Hospital Zurich, Rämistrasse 
100, 8091 Zurich, Tel.: +41 1 255 4719, Fax: +41 1 255 4590, thorsten.hornemann@usz.ch 
 
Abstract: 
The enzyme serine-palmitoyltransferase 
(SPT) catalyses the rate limiting step in 
the de-novo synthesis of sphingolipids. 
Previously the mammalian SPT was 
described as a heterodimer composed of 
two subunits - SPTLC1 and SPTLC2. 
Recently we identified a novel third SPT 
subunit (SPTLC3). SPTLC3 shows 
about 68% identity to SPTLC2 and also 
includes a PLP consensus motif. Here we 
report that the overexpression of 
SPTLC3 in HEK293 cells leads to the 
formation of two new sphingoid base 
metabolites, namely C16-sphinganine 
and C16-sphingosine. SPTLC3 
expressing cells have higher in-vitro SPT 
activities with lauryl- and myristoyl-
CoA than SPTLC2 expressing cells and 
SPTLC3 mRNA expression levels 
correlate closely with the C16-
sphinganine synthesis rates in various 
human and murine cell lines. 
Approximately 15% of the total 
sphingolipids in human plasma contain 
a C16 backbone and are found in the 
high density- and low density- but not 
the very low density lipoprotein fraction. 
In conclusion we show that the SPTLC3 
subunit is generating C16- sphingoid 
bases and that sphingolipids with a C16 
backbone constitute a significant 
proportion of human plasma 
sphingolipids. 
Introduction: 
Sphingolipids comprise a class of bioactive 
lipids that contribute to plasma membrane 
and plasma lipoprotein formation and exert 
a broad range of cellular signaling 
functions, such as cell proliferation, 
endocytosis, and the response of cells to 
inflammatory and apoptotic stress signals 
(1-4). 
Sphingolipids are derived from the 
aliphatic amino alcohol sphingosine which 
is formed from the precursors L-serine and 
palmitoyl-CoA. The condensation of serine 
with palmitoyl-CoA is catalyzed by the 
enzyme serine-palmitoyltransferase (SPT) 
[EC 2.3.1.50] and leads to the intermediate 
3-ketodihydrosphingosine (3-KDS). 3-
KDS is then rapidly converted to dihydro-
sphingosine (sphinganine) and dihydro-
ceramide. The desaturation of dihydro-
ceramide generates ceramide and the 
breakdown of ceramide by ceramidase 
finally forms sphingosine. The sphingosine 
backbone of ceramide is usually O-linked 
to a polar head group such as 
phosphocholine or carbohydrates and 
amide-linked to an acyl group. The 
combination of the sphingosine backbone 
with different head groups, in particular 
with various oligosaccharides, leads to a 
complex variety of different sphingolipid 
metabolites (5,6). Moreover, it was shown 
recently that SPT is also able to use L-
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alanine as an alternative substrate thereby 
generating the atypical sphingoid base 1-
deoxy-sphinganine (7). 
SPT belongs to the family of pyridoxal 
phosphate (PLP)-dependent α-oxoamine 
synthases (POAS). Other members of this 
family include 5-amino-levulinic acid 
synthase, 2-amino-3 ketobutyrate ligase 
(KBL) and 8-amino-7-oxononanoate 
synthase (AONS) (8). SPT is ubiquitously 
expressed and enzyme activity has been 
detected in all tissues tested so far 
including brain, lung, liver, kidney and 
muscle (9). SPT is essential for embryonic 
development and homozygous SPT 
knockout mice are not viable (10). SPT has 
been believed to be a heterodimer 
composed of two subunits SPTLC1 and 
SPTLC2. The two subunits SPTLC1 and 
SPTLC2 show a similarity at AA level of 
~20% and are highly conserved among 
species. Although both subunits seem to be 
required for enzyme activity only the 
SPTLC2 subunit contains a PLP binding 
motif (8,11). 
Recently, we identified and cloned a novel, 
third SPT subunit (SPTLC3) (12). The 
SPTLC3 sequence shows 68% homology 
to the SPTLC2 subunit and also includes a 
PLP consensus motive. The SPTLC3 gene 
is present in mammals, birds and some 
lower vertebrates like fish (D. rerio) and 
frog (X. laevis) but not in invertebrate 
lineages. The SPTLC3 mRNA has been 
detected in most human tissues with a 
particularly high expression in placenta 
(12), indicating a special role for SPTLC3 
during development and pregnancy. By 
using immunoprecipitation, native gel 
analysis, crosslinking studies and size 
exclusion chromatography it was 
demonstrated that the native SPT enzyme 
contains all three subunits and forms a 
protein complex with a molecular mass of 
about 460 kDa (13). However, since 
SPTLC2 and SPTLC3 are encoded by two 
distinct genes and expressed within the 
same cell types we assume a distinct 
function for the two subunits. One of these 
differences might be altered substrate 
affinity or enzymatic activity. This issue is 
addressed in the present study. 
 
Experimental procedures 
Cell lines 
HEK293 cells were obtained from ATCC 
and cultured in full medium (DMEM, 
Sigma) containing 10% fetal bovine serum 
(Fischer scientific) and 
Penicillin/Streptomycin (100 units per 
ml/0.1mg per ml). 
HEK293 cells were transfected with 
lipofectamine 2000 (Invitrogen) and 
selected for neomycine resistance (G418, 
400μg/ml) to generate a pool of stably 
expressing cells. The expression of each of 
the SPT subunits in the three cell lines was 
confirmed by western blots. 
Fumonisin B1 dependent accumulation 
of sphingoid bases 
Fumonisin B1 (Sigma) was added to the 
media of exponentially growing cells at a 
final concentration of 10µg/ml. As a 
negative control myriocin (10µg/ml, 
Sigma) was added together with Fumonisin 
B1. 24h after Fumonisin B1 addition, cells 
were washed twice with PBS, harvested 
and counted (coulter® Z2, Beckman 
Coulter). Synthetic C17 sphingosine 
(Avanti Polar Lipids) was added to each 
sample as an internal extraction standard. 
SPT activity assay 
Cells were grown in 10 cm dishes to 
approximately 80% confluency. Medium 
was removed and the cells were washed 
two times with PBS and harvested in 1ml 
of PBS by scraping. The suspension was 
transferred into a 1.5 ml reaction tube. 
Cells were pelleted by centrifugation (2500 
g, 2 min at 4°C) and resolved in assay 
buffer (50 mM Hepes pH 8.0, 0.5 mM 
MnCl2). The protein concentration was 
adjusted to 2 mg/ml. Protein 
concentrations of the cell lysates were 
determined using the Bradford Assay (Bio-
Rad). Albumin was used as calibration 
standard. 
The reaction cocktail for measuring in-
vitro SPT activity was composed of 400 µg 
total lysate protein, 50 mM Hepes (pH 
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8.0), 0.5 mM L-serine, 0.05 mM palmitoyl-
CoA, 20 µM pyridoxal-5’-phosphate, 0.5 
mM MnCl2, 0.1 µCi L-[U-14C]serine 
(Amersham) in a total volume of 200 µl. 
The assay was performed at 37°C for 60 
min. For the negative controls SPT activity 
was specifically blocked by the addition of 
the SPT inhibitor myriocin (40 µM, 
Sigma). The reaction was stopped by 
adding 0.5 ml methanolic-KOH:CHCl3 
(4:1) to the mixture. Methanolic KOH was 
prepared by dissolving 0.7 g KOH pellets 
in 100 ml MeOH. Lipids were extracted at 
37°C under steady agitation for 30 min. 
Subsequently 500 µl CHCl3, 500 µl 
alkaline water (100 µl NH4 (2 N) in 100 ml 
H2O) and 100 µl NH4 (2 N) was added in 
this order. Phases were separated by 
centrifugation (13000 g, 5 min) and the 
upper phase discarded. The lower phase 
was washed three times with alkaline 
water. Finally the lower organic phase was 
transferred to a scintillation vial and the 
CHCl3 evaporated under a stream of N2. 
After the addition of scintillation cocktail 
the radioactivity was quantified on a 
Scintillation Analyzer (Packard Liquid 
1900TR). 
Quantitative RT-PCR 
The mRNA was extracted using Tri 
Reagent (Molecular Research Center, Inc., 
Cincinnati, US) and transcribed to cDNA 
using oligo dT primers and Superscript III 
(Invitrogen) according to manufacturer’s 
instructions. Specific primers for the 
different SPT subunits were designed using 
the Oligo6.0 software (Molecular Biology 
Insights, Cascade, USA). Light Cycler 
PCR was performed using the DNA 
Master Kit (Roche Diagnostics, Rotkreuz, 
Switzerland) according to the 
manufacturer’s instructions. The following 
primer pairs were used (0.4 µM each): 
huSPTLC3fw: 5`- 
TGCAGCCAAGTATGATGAGTCTA -3`; 
huSPTLC3rv: 5`- 
GCAGATGCACGATGGAAC -3` 
moSPTLC3fw: 5`-
GGCTTGCAGGGAAATATG-3`; 
huSPTLC3rv: 5`-
GGATGACTGAAGTGTGGTTA-3` 
Amplification was carried out for SPTLC3: 
50 cycles, each consisting of 10 s at 95 °C; 
10 s at 61°C; 20 s at 72°C. The linearity of 
the assays was determined by serial 
dilutions of the templates for each primer 
set separately. 
Separation of plasma lipoproteins 
Plasma was isolated from healthy 
normolipidemic donors after overnight 
fasting. Three ml plasma was fractionated 
on a four step density gradient essentially 
as described (14). Ultracentrifugation was 
performed in a Beckman SW-40 swinging 
bucket rotor for 24 h at 41000 rpm at 15°C. 
Fractions (1 ml) were collected from the 
top of the centrifuge tube and analyzed for 
triglyceride, cholesterol and other lipids. 
Lipid extraction and hydrolysis 
Total lipids were extracted and, prior to 
analysis, either base or acid/ base 
hydrolyzed (15). Briefly, cells were 
resuspended in 200 µl PBS and lipids 
extracted in 1 ml extraction buffer (2 vol. 
methanol/1 vol. chloroform + 0.15 µl/ml 
C17 SO (1mM in EtOH). 100 µl of NH4 (2 
N) was added and the lipids were extracted 
under constant agitation (1 h, 37°C). 
Subsequently 0.5 ml chloroform was added 
and samples were centrifuged (12000 g, 5 
min) to separate the organic from the water 
phase. The upper (water) phase was 
discarded and the lower phase washed 
twice with 1 ml of alkaline water (1 ml 
NH4 (2 N) in 100 ml water) and dried 
under N2. For acid hydrolysis, the dried 
lipids were resupended in 200 µl 
methanolic HCl (1 N HCl/10 M water in 
methanol) and kept at 65°C for 12-15 
hours. The solution was neutralized by the 
addition of 40 µl KOH (5 M) and 
subsequently subjected to as follows: 0.5 
ml extraction buffer (4 vol. 0.125 M KOH 
in methanol + 1 vol. chloroform) was 
added and mixed. Subsequently, 0.5 ml 
chloroform, 0.5 ml alkaline water and 100 
µl NH4 (2 N) was added in this order. 
Liquid phases were separated by 
centrifugation (12000 g, 5 min). The upper 
phase was aspirated and the lower phase 
washed twice with alkaline water. Finally, 
the lipids were dried by evaporation of the 
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chloroform phase under N2 and subjected 
to LC-MS analysis. 
Plasma lipids were analyzed from 100 µl 
of human EDTA-treated plasma which was 
treated in the same manner. 
LC-MS 
Extracted lipids were solubilized in 56.7% 
methanol/33.3% ethanol/10% water and 
derivatized with ortho-phthaldialdehyde 
(OPA, Sigma) (15). The lipids were 
separated on a C18 column (Uptispere 
120Å, 5µm, 125x2mm, Interchim, France) 
and analyzed by a serial arrangement of a 
fluorescence detector (HP1046A, Hewlett 
Packard) followed by a MS detector 
(LCMS-2010A, Shimadzu). APCI 
(atmospheric pressure chemical ionisation) 
was used for ionisation. Non natural C17 
sphingosine (Avanti Polar Lipids) was 
used as the internal standard. 
Results 
SPTLC3 expressing cells generate C16 
sphingoid bases 
The human SPT subunits SPTLC1, 
SPTLC2 and SPTLC3 were cloned into a 
pcDNA3.1 expression vector and 
expressed in HEK293 cells as reported 
earlier (12). HEK293 cells were chosen 
since they express low endogenous levels 
of SPTLC3 mRNA (Fig.4A). All subunits 
were expressed at comparable levels as 
demonstrated by western blot analysis and 
showed no signs of degradation (12). 
To determine if SPTLC3 expressing cells 
generated more, or other, sphingoid bases 
we compared the spectrum of de novo-
synthesized sphingoid bases between 
SPTLC3 deficient (HEKCnt) and SPTLC3 
overexpressing cells (HEKSPTLC3). This 
was done by blocking the de novo 
synthesis pathway at the step of the 
ceramide synthase (CerS) with Fumonisin 
B1 (FB1). The inhibition of CerS leads to a 
time dependent accumulation of its 
substrate sphinganine (SA). Hence, 
potential side products of the SPT reaction 
are also accumulating under these 
conditions (7). The accumulated lipids 
were extracted 24h after the addition of 
FB1, derivatized with ortho-
phtaldialdehyde (OPA) and analyzed on a 
C18 reverse phase column with a serially 
arranged fluorescence and MS detector 
(15). 
In the presence of FB1 we observed a 
significant accumulation of sphinganine 
(Fig.1A) whereas no SA accumulation was 
seen when SPT activity was blocked with 
myriocin. In parallel we observed the 
appearance of a second unknown peak 
which eluted prior to SA after 8.2 min. 
Because of similar retention times this 
peak was partly overlaid by the internal 
standard (C17-SO) which was added for 
normalization. (Fig.1B). Accumulation of 
SA but also of this unknown peak was not 
observed when SPT activity was inhibited 
with myriocin. This observation indicates 
that the unknown metabolite is a product of 
the SPT reaction. Subsequent MS analysis 
revealed that the unidentified metabolite 
had an m/z of 450.3 (as an OPA derivate). 
For this mass the single ion chromatogram 
revealed a single peak with the same 
retention time as seen in the fluorescence 
chromatogram (Fig.1B). This signal was 
not seen in the presence of myriocin (Fig. 
1C). The unknown metabolite (m/z 450.3) 
showed a mass difference to sphinganine 
(m/z 478.3) of 28 Da which equals the 
mass of a CH2CH2 group and suggests that 
the unknown metabolite is dihydro-
sphingosine (SA) with a C16, instead of a 
C18, carbon chain (C16-SA). This 
metabolite could be formed by the 
conjugation of L-serine with myristoyl-
CoA instead of palmitoyl-CoA. 
 
SPTLC3 has higher activity with C12 and 
C14 acyl-Co-A 
To test this hypothesis we compared the in-
vitro SPT activity with various acyl-CoA 
substrates in extracts from control, 
SPTLC1-, SPTLC2- and SPTLC3-
overexpressing cells. All acyl-CoAs were 
used at the same concentration (50 µM). In 
comparison the SPTLC3 expressing cells 
showed a significantly higher activity with 
lauryl-CoA and myristoyl-CoA than did 
the control, SPTLC1- or SPTLC2-
expressing cells (Fig.2A). This suggests 
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that the SPTLC3-mediated SPT activity is 
primarily responsible for the generation of 
sphingoid bases with a C14 or C16 backbone 
whereas the SPTLC2 subunit seems to be 
more specific for longer acyl-CoAs thereby 
forming C18 and C20-sphingoid bases.  
 
C16-SA generation is stimulated by serine  
The addition of L-serine to the cell culture 
medium generally stimulates SPT activity 
and SA de-novo synthesis (7). To 
determine if L-serine also stimulated 
SPTLC3 mediated C16-SA generation, we 
compared the accumulation of C16-SA in 
FB1 treated HEKCnt and HEKSPTLC3 cells 
which were cultured either in regular 
medium or in medium that was 
supplemented with L-serine (10 mM). The 
normally cultured HEKSPTLC3 cells showed 
a clear accumulation of C16-SA in the 
presence of FB1, whereas HEKCnt cells did 
not show any accumulation under these 
conditions (Fig. 2B). In the cells which 
were cultured at elevated serine levels the 
accumulated sphingoid bases increased 
significantly. For HEKSPTLC3 cells we 
observed a 3-fold increase in SA 
accumulation (data not shown) and a 4-
fold increase in the accumulation of C16-
SA (Fig. 2B). Even in HEKCnt cells a small 
accumulation of C16-SA was detected 
under these conditions. 
 
Kinetic analysis of SPTLC3 activity 
To obtain further insight into the 
enzymatic mechanism we compared the 
kinetics for myristoyl-CoA and palmitoyl-
CoA in HEKCnt and HEKSPTLC3 cells. For 
palmitoyl-CoA the enzyme followed a 
Michaelis-Menten kinetics up to a 
concentration of about 0.1 mM (Fig. 3A). 
The kinetics with palmitoyl-CoA was 
essentially the same in HEKCnt and 
HEKSPTLC3 cells. At palmitoyl-CoA 
concentrations above 0.15 mM substrate 
inhibition was observed in accordance to 
earlier reports (16,17). Also the Hanes-
Woolf plot (18) showed a linear 
relationship between [S] and 1/v up to a 
palmitoyl-CoA concentration of 0.1mM 
(Fig. 3A). For myristoyl-CoA we observed 
an about 5-fold higher activity in 
HEKSPTLC3 cells compared to HEKCnt cells 
(Fig. 3B). As for palmitoyl-CoA we also 
observed an inhibitory effect of myristoyl-
CoA at higher concentrations. For both 
substrates the optimal activity was in a 
concentration range of 0.1-0.125 mM. 
Km and Vmax values (Fig. 3C) were 
deduced from the Hanes-Woolf plots and 
confirmed by a hyperbolic regression 
analysis (19). Both methods gave similar 
results. 
For palmitoyl-CoA the kinetic parameters 
Vmax and Km were similar in HEKCnt and 
HEKSPTLC3 cells whereas for myristoyl-
CoA both cell lines showed significant 
differences. Due to the low activity in 
HEKCnt cells a precise determination of 
Vmax and Km for myristoyl-CoA was not 
possible. Nevertheless, it was obvious that 
the Vmax for myristoyl-CoA is 
significantly lower in HEKCnt compared to 
HEKSPTLC3 cells. The Kms for palmitoyl-
CoA and myristoyl-CoA in HEKSPTLC3 
cells were comparable whereas the 
maximal velocity for myristoyl-CoA was 
about 50% lower than for palmitoyl-CoA 
(Fig. 3C). 
 
SPTLC3 mRNA levels correlate with C16-
SA accumulation in FB1 blocked cells 
To further confirm that the generation of 
C16-SA is linked to the expression of 
SPTLC3, we analysed the SPTLC3 mRNA 
levels in various human and non-human 
cell lines (Fig.4A). Some cell lines like 
HEK293 or the human monocytic cell line 
THP1, showed very low SPTLC3 mRNA 
expression whereas intermediate levels 
were found in HepG2, COS and NIH/3T3 
cells. The highest SPTLC3 mRNA levels 
were in the trophoblast lines JAR and JEG-
3 as reported earlier (12). The SPTLC3 
mRNA levels showed a close correlation 
with the levels of accumulated C16-SA in 
these cells (Fig. 3B), providing further 
evidence that C16-sphingoid bases are 
primarily generated by SPTLC3.  
 
C16-SA is metabolized to C16-SO 
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The observation that C16-SA accumulates 
in the presence of the CerS inhibitor FB1 
indicates that C16-SA is also a substrate for 
CerS. Consequently, the generated C16-SA 
is further metabolized to C16-dihydro-
ceramide and to C16-ceramide. The 
degradation of C16-ceramide by ceramidase 
would finally lead to the generation of C16-
sphingosine (C16-SO). 
To test whether the SPTLC3-expressing 
cells also produce C16-SO we compared 
the total sphingoid base content between 
HEKCnt and HEKSPTLC3 cells. In view of 
the great variety of fatty acids and possible 
head groups that can be attached to the 
sphingoid backbone, a complete analysis 
of all possible C16-ceramide variants is a 
demanding task and will be addressed in 
future studies. To simplify the analysis we, 
therefore, subjected the extracted lipids to 
acid and base hydrolysis. Under acidic 
conditions the amide bond of the 
conjugated fatty acid is released whereas 
the O-linked phosphoester and 
carbohydrate moieties of the sphingoid 
base head group are removed under basic 
conditions. This procedure allowed the 
quantification of the total C16 and C18 
sphingoid base levels in the cells. The 
molecular mass of SO and SA differs, due 
to the Δ4 double bond, by two Daltons. As 
described above we observed a significant 
FB1 dependent accumulation of C16-SA 
(m/z 450.3) in HEKSPTLC3 cells (Fig. 5A). 
No signal in the single mass chromatogram 
for C16-SO (m/z 448.3) was seen because 
the metabolism of the de-novo formed C16-
SA was blocked in the presence of FB1. In 
contrast, analysis of the acid/base treated 
extract from HEKSPTLC3 cells showed a 
pronounced peak with the m/z ratio of C16-
SO (448.3). Interestingly, HEKCnt cells 
also contained small but detectable 
amounts of C16-SO but did not show the 
accumulation of C16-SA in the presence of 
FB1. This could be possibly explained by 
an uptake of C16-ceramide from the 
medium as an external source since 
mammalian serum, including fetal calf 
serum (FCS) contains considerable 
amounts of C16-based sphingolipids (see 
also Fig. 6). 
To further demonstrate that the identified 
metabolite is C16-SO we compared its 
retention time with respect to other 
sphingoid bases with different carbon 
chains. On a C18 reverse phase column 
sphingoid bases show a logarithmic 
correlation between retention time and 
their carbon chain length (Fig. 5B). 
Regression analysis of this function 
revealed a theoretical retention time for 
C16-SO of 6.5 min which is in agreement 
with the observed retention time (6.45 min) 
of the identified metabolite (Fig. 3A,B). 
Our studies also show that the C16-SO 
levels of acid/base treaded cell lines 
closely correlate with C16-SA which can 
be assumed to be the metabolic precursor 
(Fig. 5C). 
 
Up to 15% of human plasma sphingolipids 
are based on a C16-backbone 
The observation that SPTLC3 is 
responsible for the generation of C16-
sphingoid bases raised the questions of 
whether these lipids are also present in 
human plasma and how they are 
transported in plasma. 
We analyzed plasma samples of 20 healthy 
donors. The plasma was acid/base treated 
and analyzed by LC-MS. The analysis 
showed that the majority of plasma 
sphingolipids are based on a C18 
sphingosine backbone. Nevertheless, an 
astonishingly high fraction of plasma 
sphingolipids was found with a C16-SO 
backbone (Fig. 6A). The proportion of C16-
SO in total plasma SO may be as high as 
15%. The fraction of plasma sphingolipids 
which contained a SA backbone was much 
lower. About 4% of the plasma 
sphingolipids contained a sphingosine 
backbone whereas 15-20% of the total SA 
contained a C16-backbone. 
The analysis of lipoprotein fractions which 
were isolated by ultracetrifugation 
demonstrated that both, the C16- and the 
C18-sphingolipids are present in the LDL 
and HDL fractions but not in the VLDL 
fraction (Fig. 6B). In comparison to total 
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cholesterol and triglyceride the 
sphingolipids showed a shoulder in 
fractions 9 and 10 indicating that they are 
also part of a denser HDL subfraction. 
Discussion 
The fact that SPTLC2 and SPTLC3 both 
form a catalytically active SPT 
holoenzyme raises questions about the 
functional differences between these two 
isoforms. Here we report that the presence 
of SPTLC3 enables the enzyme to 
metabolize shorter acyl-CoAs, like lauroyl- 
and myristoyl-CoA in contrast to the 
predominant usage of palmitoyl-CoA by 
SPT in the absence of SPTLC3. In 
HEK293 cells, which endogenously 
express insignificant levels of this subunit 
only, we observed the appearance of two 
novel sphingolipid metabolites in cells 
overepxressing SPTLC3. The two novel 
metabolites were identified as C16-SA and 
C16-SO. SPTLC3 expressing cells showed 
a significantly higher in-vitro SPT activity 
with lauroyl – and myristoyl-CoA 
compared to SPTLC1- or SPTLC2-
overexpressing cells. The presence of these 
metabolites correlated closely with 
SPTLC3 mRNA expression in various 
human and murine cell lines. A kinetic 
comparison between HEKCnt and 
HEKSPTLC3 cells showed a significantly 
higher Vmax for myristoyl-CoA in the 
SPTLC3 expressing cells whereas Vmax 
for palmitoyl-CoA was the same in both 
cell lines. This observation suggests that 
the reaction with palmitoyl-CoA is 
primarily catalyzed by the (endogenously 
expressed) SPTLC2 subunit and is not 
influenced by the presence of SPTLC3. 
Quantitative RT-PCR analysis of HEKCnt 
and HEKSPTLC3 cells showed that SPTLC1 
and SPTLC2 mRNA levels do not change 
upon SPTLC3 expression (data not 
shown), implying that the SPTLC3 subunit 
has a rather specific affinity for myristoyl-
CoA and only a minor affinity for 
palmitoyl-CoA. Otherwise the 
overexpression of SPTLC3 would have 
influenced the Vmax for palmitoyl-CoA as 
well. These findings suggest that SPTLC3 
is predominantly responsible for the 
generation of C14 and C16-sphingoid bases, 
making SPTLC3 functionally distinct from 
the SPTLC2 subunit. Previously, Merrill 
and co-workers analyzed SPT activities 
with different fatty acid-CoA thioesters in 
microsomes of various rat tissues (9). 
Some of the tested tissues showed higher 
activities with shorter alkyl chains than 
others. This observation might be 
explained by different SPTLC3 expression 
levels in these tissues. 
The identification of three SPT subunits 
two of which contain a binding site for the 
PLP cofactor, raises further questions 
about the structure of the SPT holoenzyme. 
In analogy to other members of the POAS 
family it has been assumed that the active 
SPT is a heterodimer. However, size 
exclusion chromatography and cross-
linking data indicate that the SPT is a 
holoenzyme and simultaneously composed 
of all three subunits (13). It is not clear yet 
whether all three subunits are required to 
form an active SPT enzyme. The fact that 
some cells, like HEK293, express only 
minor levels of this subunit indicate that 
SPTLC3 is not essential for forming an 
active enzyme. Nevertheless, the size 
exclusion chromatography data revealed a 
molecular mass of 460 kDa for the active 
SPT complex – independent of the 
presence or absence of SPTLC3 (13). This 
might be explained by a dynamic 
stoichiometry of the complex in which the 
SPTLC2 and SPTLC3 subunits can 
substitute for each other. A second 
possibility would be an association with 
further yet unidentified proteins. In this 
context it is interesting that, very recently, 
a fourth SPT subunit was reported (20). 
Han et al. identified two short polypeptides 
which interact with SPTLC1 and SPTLC2. 
The expression of these two proteins 
stimulated SPT activity and modulated the 
substrate preference of SPT towards the 
use of longer acyl-CoA (20), indicating a 
regulatory function for these polypeptides. 
However, it is currently not clear how 
these new proteins can be integrated into 
the concept of SPT structure and function.  
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Besides C16-SA, we also observed the 
presence of C16-SO in acid/base treated 
lipid extracts of SPTLC3-expressing cells. 
Since a C16-SO standard is commercially 
not available the identification of this 
metabolite is based on several indirect 
pieces of evidence. The conformity of the 
identified C16-SO is based on its mass (Fig. 
5A), the retention time (Fig. 5B) and the 
correlation with its precursor C16-SA (Fig. 
5C). We also confirmed the presence of 
this metabolite in lipid extracts from 
Drosophila (data not shown); insects have 
been reported to generate primarily C16-
sphingoid bases (21). Thus, it appears that 
C16-SA can be further metabolized to C16-
dihydro-ceramide/C16-ceramide and finally 
also degraded to C16-SO. This indicates 
that potentially all types of sphingolipids, 
including glyco- and phosphosphingolipid, 
could be formed on the basis of a C16 
sphingosine backbone. These findings 
greatly expand the already huge variety of 
possible sphingolipid variants and might 
also influence the understanding of these 
lipids. In comparison to C18 sphingoid 
bases sphingoid bases with a C16 backbone 
are considerably less hydrophobic and 
hence likely exhibit significant differences 
in biophysical properties. The C16 -
sphingolipids will exchange much more 
rapidly with a hydrophilic environment 
which might influence their subcellular 
localization and their distribution in 
membranes which, in turn, may have 
important implications for transport and 
translocation as well as cellular signal 
transduction. 
Curiously there are only few reports on 
C16-sphingolipids in the literature. 
Sphingoid bases with a C14 and C16 carbon 
chain are the predominant sphingolipids in 
insects (21,22). Recent studies of a marine 
virus (Coccolithovirus) revealed that the 
viral genome contains a cluster of putative 
sphingolipid biosynthetic genes, including 
an SPT-like enzyme (23) that utilizes 
myristoyl-CoA and therefore generates C16 
sphingoid bases when expressed in yeast. 
Sphingoid bases with 16 carbon atoms 
were also found in bovine milk (24,25) and 
as a part of the black epidermis from the 
antarctic minke whale (26). A few earlier 
reports indicate the presence of C16 
sphingoid bases in human plasma (27,28). 
Interestingly, certain human tissues like 
placenta show pronounced expression of 
SPTLC3 (12) and contain high levels of 
C16 sphingoid bases (data not shown). This 
was also seen in human trophoblast cell 
lines like JEG-3 and JAR in which high 
SPTLC3 mRNA expression correlated 
with high C16 sphingoid base levels (Fig. 
4B). The unusually high level of SPTLC3 
mRNA in placental tissue suggests a 
specific physiological role for these 
metabolites during embryogenesis and 
pregnancy. Also, the finding that 
approximately 15% of human plasma 
sphingolipids contain a C16 backbone 
indicates a significant physiological 
relevance of these metabolites. The source 
of the C16 sphingolipids in plasma is not 
yet known but we have demonstrated that 
plasma C16- and C18-sphingoid bases are 
transported in HDL and LDL but not in the 
VLDL lipoproteins fraction (Fig. 6B) 
indicating that C16-sphingoid bases are at 
least partly metabolized by the liver. In this 
respect it is interesting that elevated 
plasma sphingolipid levels are associated 
with an increased risk of developing 
atherosclerosis and coronary heart disease 
(29,30). Myriocin lowered plasma 
sphingolipids in ApoE knock-out mice and 
significantly reduced the formation of 
atherosclerotic lesions in these mice and 
showed a significant delay of disease 
progression (31-33). Since treatment with 
myriocin would be expected to lower the 
levels of both C16- and C18-based 
sphingolipids it would be interesting to 
determine if one of the two subclasses is 
primarily involved in the pathogenesis of 
atherosclerosis. In this context, analysis of 
the C16-sphingoid bases in plasma of 15 
wild-type mice (C57BL/6) showed 
significantly lower levels (about 90% less)  
of C16 sphingoid bases in mice although 
the levels of the C18 sphingoid bases were 
comparable (data not shown). Low levels 
of C16-sphingoid bases were also seen in 
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 9
rat plasma (data not shown). On the other 
hand, rodent and human cell lines showed 
similar SPTLC3 activities when 
normalized to mRNA expression (Fig. 4B), 
indicating that the lower C16-SO levels in 
mouse plasma are due to a different C16-
SO metabolism and not simply caused by a 
lower SPTLC3 activity in mice. It should 
therefore be considered that rodents and 
humans are distinct with respect to C16-
sphingolipid metabolism, a fact that should 
be kept in mind when working with rodent 
models of disease. In conclusion, the 
observation that SPTLC3 is found in all 
higher vertebrates and that its presence is 
primarily linked to the generation of C16 
sphingoid bases, indicate an evolutionarily 
conserved need for these types of 
sphingolipids. However, the distribution, 
metabolic fate and biochemical properties 
of these lipids have to be addressed in 
future studies. 
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Figure legends 
Figure 1: A) HPLC analysis of accumulated lipids in FB1-treated HEKSPTLC3 cells. 
HEKSPTLC3 cells were cultured in the presence of Fumonisin B1 (FB1) for 24 h. The 
accumulated sphingoid bases were extracted, derivatized with ortho-phthaldialdehyde (OPA) 
and analyzed on a C18 reverse phase column with fluorescence detection. In the presence of 
FB1 (black line) sphinganine accumulated (SA, RT 13.5min) and a second unknown 
metabolite appeared (RT 8.2 min). This unknown metabolite was partially superimposed by 
the internal standard (C17-SO) due to the similar retention times. No accumulation of these 
metabolites was observed when the cells were treated with the SPT inhibitor myriocin (grey 
line). B) MS analysis with a serially arranged MS detector revealed an m/z of 450.3 for the 
unknown metabolite. The single ion chromatogram showed a single peak (m/z 450.3, grey 
line) with a retention time identical to that observed in the fluorescence spectrum. The internal 
standard (C17-SO, m/z 462.3, thin black line) eluted shortly before the unknown metabolite. 
C) SA and the unknown metabolite did not accumulate in FB1+myriocin-treated HEKSPTLC3 
cells. 
 
Figure 2: A) In vitro SPT activity with various acyl-CoA substrates in control, SPTLC1, 
SPTLC2 and SPTLC3 overexpressing HEK293 cells. SPTLC3 overexpressing cells showed a 
significantly higher activity with lauroyl (C12) - and myristoyl (C14) -CoA compared to cells 
expressing the empty vector or the subunits SPTLC1 or SPTLC2. The activity with stearoyl 
and oleoyl-CoA was comparable for all cell lines. (For comparison the activity with 
palmitoyl-CoA is defined as 100%). 
B) Effect of serine supplementation on C16-SA generation in cultured HEKCnt and HEKSPTLC3 
cells. Cells were treated with FB1 (24 h) and the accumulated C16-SA quantified by LC-MS. 
A significant buildup of C16-SA was seen in SPTLC3-expressing cell but not in control cells. 
The addition of L-serine (10 mM) to the cell culture medium of SPTLC3 cells increased the 
generation of C16-SA ~ 4-fold. 
 
Figure 3: Kinetic analysis of SPTLC3 activity in HEKCnt and HEKSPTLC3 for palmitoyl-CoA 
and myristoyl-CoA. A) For palmitoyl-CoA both cell lines show an identical kinetic behavior. 
The kinetics followed a Michaelis-Menten curve up to a substrate concentration of 0.1 mM 
(left panel). Above that concentration activity was reduced due to substrate inhibition. The 
Hanes-Woolf representation (right panel) revealed an inverse linear correlation between 
substrate concentration and reaction velocity. B) HEKSPTLC3 cells showed significantly 
increased activity with myristoyl-CoA in comparison to control cells (HEKCnt). Also with 
myristoyl-CoA we observed a Michaelis-Menten kinetic up to 0.1mM and substrate inhibition 
at higher concentrations. Maximal activity was seen at myristoyl-CoA concentrations between 
0.1-0.125mM. The Hanes-Woolf plot for myristoyl-CoA also showed an inverse linear 
correlation between substrate concentration and reaction velocitiy. C) Vmax and Km values 
were deduced from the Hanes blot and confirmed by a hyperbolic regression analysis. With 
palmitoyl-CoA the Vmax and Km values were identical for both cell lines whereas Vmax for 
myristoyl-CoA was significantly lower in control cells (HEKCnt) compared to the SPTLC3-
expressing cells (HEKSPTLC3). In HEKSPTLC3 cells, the Km for myristoyl-CoA and palmitoyl-
CoA were comparable whereas Vmax for myristoyl-CoA was about 50% lower than for 
palmitoyl-CoA. For HEKCnt cells the Km and Vmax of myristoyl-CoA could not be reliably 
determined (n.d.) due to low enzymatic activity with myristoyl-CoA in these cells.  
 
Figure 4: A) Quantitative analysis of SPTLC3 mRNA expression in human and non-human 
cell lines. Cell lines like HEK293, THP1 or Hela express SPTLC3 in low amounts whereas 
higher expression was observed in the trophoblast cell lines JAR and Jeg3. B) Correlation of 
SPTLC3 mRNA expression and the accumulated C16-SA in FB1-treated cells. Cells were 
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incubated with FB1 for 24h and the accumulated C16-SA analyzed by LS-MS. We found a 
good correlation between SPTLC3 mRNA expression levels and the levels of accumulated 
C16-SA (R2 = 0.98). 
 
Figure 5: A) Identification of C16-SO in total lipid extract of HEKSPTLC3 cells. The diagram 
shows the single ion chromatograms for C16-SA (450.3) and C16-SO (448.3) in FB1 blocked 
and acid/base treated lipid extracts from HEKCnt and HEKSPTLC3 cells. The FB1 treated 
HEKSPTLC3 cells showed a significant accumulation of C16-SA (450.3) which was not seen in 
the HEKCnt cells. No C16-SA was observed in the acid/base treated lipid extracts from 
HEKSPTLC3 or HEKCnt cells. In its place a conspicuous peak appeared with the mass of C16-SO 
(m/z 448.3) and a retention time of 6.5 min. This peak was significantly higher in HEKSPTLC3 
than in HEKCnt cells. B) Functional relationship between retention time and carbon chain 
length of sphingoid bases. SA and SO standards with various carbon chain lengths were 
separated by HPLC. The dihydro-form (SA) generally eluted later than the corresponding SO 
form. The retention times showed a logarithmic relationship to the carbon chain length of the 
sphingoid bases. Based on a logarithmic regression analysis, a theoretical retention time of 
6.45 min was calculated for C16-SO which is in close concordance with the observed retention 
time for the C16-SO peak (6.5 min). C) C16-SA and C16-SO levels in acid/base treated lipid 
extracts from various human and murine cell lines. The C16-SO levels showed a good 
correlation to the precursor C16-SA (R2 = 0.908). 
 
Figure 6: a) C18- and C16-SO levels in human plasma. Plasma of 20 healthy donors was 
acid/base treated and analyzed by LC-MS. The analysis revealed that the majority of plasma 
sphingolipids are based on a SO backbone whereas about 4% of the plasma sphingolipids 
contain a SA backbone. Up to 15% of the plasma sphingosine and sphinganine fraction was 
based on a C16-backbone. B) C18- and C16-SO are components of plasma LDL and HDL-
lipoprotein fractions. Human plasma was fractionated by a four step density gradient 
ultracentrifugation. The individual fractions were assayed for cholesterol (Chol; dotted line), 
triglycerides (TG; dashed line), C18-SO (rhombus) and C16-SO (square). The cholesterol and 
TG profile indicated the peak for LDL in fraction 4 and for HDL in fractions 7 and 8. In 
parallel the highest C18-SO and C16-SO concentrations were found in these fractions. The 
elevated TG concentrations in fraction 1 indicated the presence of VLDL which did not 
contain C18-SO or C16-SO. The sum of all fractions was defined as 100% and values are given 
in percent of total. 
 13
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 3, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
7.0 8.0 9.0 10.0 11.0 12.0 13.0 14.0 15.0 16.0 17.0 min
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0
1
2
3
4
5
6
7
de
te
ct
or
 s
ig
na
l (
V)
ar
bi
tra
ry
 u
ni
ts
HPLC (fluorescence)
SA
SA
C16-SA
C16-SA
Int. STD
(C17-SO)
Int. STD
Int. STD
478.3
462.3
450.3
478.3
462.3
450.3
+myriocin
m/z
Fig. 1
0
1
2
3
4
5
6
7
ar
bi
tra
ry
 u
ni
ts
MS (single ion chromatogram)
MS (single ion chromatogram)
7.0 8.0 9.0 10.0 11.0 12.0 13.0 14.0 15.0 16.0 17.0 min
7.0 8.0 9.0 10.0 11.0 12.0 13.0 14.0 15.0 16.0 17.0 min
A
B
C
m/z
 
 14
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 3, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
Fig. 2
A
0
20
40
60
80
100
120
140
160
pm
ol
 / 
m
ill
io
n 
ce
lls
L-serine+ +- -
HEKCnt HEK SPTLC3
B
0
20
40
60
80
100
120
co
nt
ro
l
S
P
TL
C
1
S
P
TL
C
2
S
P
TL
C
3
oleoyl-CoA
ac
tiv
ity
 (%
)
co
nt
ro
l
S
P
TL
C
1
S
P
TL
C
2
S
P
TL
C
3
stear-CoA
co
nt
ro
l
S
P
TL
C
1
S
P
TL
C
2
S
P
TL
C
3
palm-CoA
co
nt
ro
l
S
P
TL
C
1
S
P
TL
C
2
S
P
TL
C
3
myr-CoA
co
nt
ro
l
S
P
TL
C
1
S
P
TL
C
2
S
P
TL
C
3
lauryl-CoA
 
 15
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 3, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
v
(m
m
ol
/m
g/
m
in
)
0
10
20
30
40
50
60
0.05 0.1 0.15
[S]/v
palm-CoA [mM]
0
100
200
300
400
500
600
700
800
0.05 0.1 0.15
[S]/v
myr-CoA [mM]
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
0 0.05 0.1 0.15 0.2 0.25
palm-CoA [mM]
v
(m
m
ol
/m
g/
m
in
)
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
0 0.05 0.1 0.15 0.2 0.25
myr-CoA [mM]
Vmax
(mmol/mg/min)
palm-CoA 0.6 0.6
myr-CoA 0.3
Km
(mM)
palm-CoA 0.05 0.04
myr-CoA n.d. 0.03
A
B
C
HEKCnt HEKCnt HEK SPTLC3HEKSPTLC3
Fig. 3
n.d.
-0.05-0.1-0.15
-0.05-0.1
 
 16
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 3, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
HEK293 THP1 Hela HepG2 RAW COS1 3T3 JAR JEG-3
S
P
TL
C
3 
m
R
N
A
(p
g/
µg
 to
ta
l m
R
N
A
)
A
B
R2 = 0.9867
0
50
100
150
200
250
0.0 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18 0.20
SPTLC3 mRNA (pg)
C
16
S
A
(p
m
ol
/m
ill
io
n 
ce
lls
)
RAW/HepG2
3T3
JAR
JEG-3
Fig. 4
COS1
 
 17
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 3, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
010
20
30
40
50
60
70
0 1 2 3 4 5 6 7
SA (µmol/mill.cells)
R  =0.908 2
A
C
Fig. 5
B
RT(SA) = 0.1157e
0.2691x
RT(SO) = 0.0912e0.2664x
0
5
10
15
20
25
30
15 16 17 18 19 20 21
carbon chain lenth
re
te
nt
io
n 
tim
e
(m
in
)
SO
SA
5.0 7.5 10.0 12.5 15.0 17.5
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
FB1 block
acid hydrolysis
450.3 (C16-SA)
448.3 (C16-SO)
450.3 (C16-SA)
448.3 (C16-SO)
450.3 (C16-SA)
448.3 (C16-SO)
450.3 (C16-SA)
448.3 (C16-SO)
RT (min)
M
S
 s
ig
na
l (
A
U
)
(m/z)
HEKCnt
HEKSPTLC3
HEKCnt
HEKSPTLC3
S
O
(µ
m
ol
/m
ill
.c
el
ls
)
JEG-3
JAR
3T3
HepG2
RAW
HEK293
 
 18
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 3, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
µm
ol
/l
0
50
100
150
200
250
300
350
C18-SO C16-SO
Fig. 6
A
0
5
10
15
20
25
30
1 2 3 4 5 6 7 8 9 10 11 12
B
LDL HDLVLDL
Chol
TG
C16-SO
C18-SO
pe
rc
en
t o
f t
ot
al
Fraction
0
2
4
6
8
10
C18-SA C16-SA
µm
ol
/l
 
 
 19
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 3, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
